Urine-derived podocytes from steroid resistant nephrotic syndrome patients as a model for renal-progenitor derived extracellular vesicles effect and drug screening

• Published in: Journal of translational medicine 2024-08, Vol.22 (1), p.762-16
• Main Authors: Tanzi, Adele, Buono, Lola, Grange, Cristina, Iampietro, Corinne, Brossa, Alessia, Arcolino, Fanny Oliveira, Arigoni, Maddalena, Calogero, Raffaele, Perin, Laura, Deaglio, Silvia, Levtchenko, Elena, Peruzzi, Licia, Bussolati, Benedetta
• Format: Article
• Language: English
• Subjects: Alport syndrome; Cell organelles; Drug Evaluation, Preclinical; Drug Resistance; Epithelial cells; Exosomes; Extracellular Vesicles - metabolism; Health aspects; Humans; Infant, Newborn; Kidney - metabolism; Kidney - pathology; Kidney glomerulus; Male; Models, Biological; Nephrotic syndrome; Nephrotic Syndrome - drug therapy; Nephrotic Syndrome - metabolism; Nephrotic Syndrome - pathology; Pediatric research; Permeability; Personalized therapy; Physiological aspects; Podocytes - drug effects; Podocytes - metabolism; Podocytes - pathology; Renal progenitor cells; Stem Cells - metabolism; Steroid-resistant nephrotic syndrome; Steroids - pharmacology; Testing
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-024-05575-z

Personalized disease models are crucial for evaluating how diseased cells respond to treatments, especially in case of innovative biological therapeutics. Extracellular vesicles (EVs), nanosized vesicles released by cells for intercellular communication, have gained therapeutic interest due to their ability to reprogram target cells. We here utilized urinary podocytes obtained from children affected by steroid-resistant nephrotic syndrome with characterized genetic mutations as a model to test the therapeutic potential of EVs derived from kidney progenitor cells (nKPCs). EVs were isolated from nKPCs derived from the urine of a preterm neonate. Three lines of urinary podocytes obtained from nephrotic patients' urine and a line of Alport syndrome patient podocytes were characterized and used to assess albumin permeability in response to nKPC-EVs or various drugs. RNA sequencing was conducted to identify commonly modulated pathways after nKPC-EV treatment. siRNA transfection was used to demonstrate the involvement of SUMO1 and SENP2 in the modulation of permeability. Treatment with the nKPC-EVs significantly reduced permeability across all the steroid-resistant patients-derived and Alport syndrome-derived podocytes. At variance, podocytes appeared unresponsive to standard pharmacological treatments, with the exception of one line, in alignment with the patient's clinical response at 48 months. By RNA sequencing, only two genes were commonly upregulated in nKPC-EV-treated genetically altered podocytes: small ubiquitin-related modifier 1 (SUMO1) and Sentrin-specific protease 2 (SENP2). SUMO1 and SENP2 downregulation increased podocyte permeability confirming the role of the SUMOylation pathway. nKPCs emerge as a promising non-invasive source of EVs with potential therapeutic effects on podocytes with genetic dysfunction, through modulation of SUMOylation, an important pathway for the stability of podocyte slit diaphragm proteins. Our findings also suggest the feasibility of developing a non-invasive in vitro model for screening regenerative compounds on patient-derived podocytes.